Plant-Derived Nanoparticles for Autoimmune Disease Treatment

A scientific review published recently in the International Journal of Molecular Sciences examines how plant-derived exosome-like nanoparticles (PELNs) could offer new approaches to treating autoimmune diseases by regulating immune responses, reducing inflammation, and delivering therapeutic compounds to affected tissues.

What are nanoparticles, and how could they help treat autoimmune disease?

Nanoparticles are extremely small particles that scientists can design or modify to interact with specific cells and tissues. In autoimmune disease research, they are being investigated as a way to deliver medications more precisely, regulate harmful immune responses, and potentially reduce the need for widespread immune suppression.

Plant-derived exosome-like nanoparticles are one emerging approach. Unlike some synthetic nanoparticles, these particles are obtained from plant materials and may carry naturally occurring biological compounds alongside additional therapeutic molecules.

For more background, see GAI’s Nanotechnology Breakthroughs in Autoimmune Disease Treatment .

Researchers at Shanxi University of Chinese Medicine in China reviewed laboratory and animal studies involving rheumatoid arthritis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), and experimental diabetes models.

How Plant-Derived Nanoparticles May Regulate Inflammation

PELNs are microscopic particles extracted from plants such as ginger, ginseng, and grapes. They contain biological substances, including lipids, proteins, and RNA, that may influence immune-cell activity and inflammatory processes.

The review highlights several promising findings:

  • Rheumatoid arthritis: Ginger-derived nanoparticles modified with folic acid have been investigated for their ability to target inflammatory macrophages, while ginseng-derived particles have shown potential to reduce inflammatory signaling and inhibit cells involved in bone erosion.
  • Inflammatory bowel disease: Nanoparticles from plants including ginger, ginseng, and broccoli have demonstrated effects on intestinal immune cells, inflammation, and the gut microbiome in experimental models.
  • Type 1 diabetes-related research: Preliminary studies using experimental diabetes models suggest possible benefits for pancreatic function, oxidative stress, and tissue repair, although they do not establish an effect on the underlying autoimmune process.

Engineering Nanoparticles for Targeted Treatment

Diagram showing how plant-derived exosome-like nanoparticles are engineered through drug loading and surface modification for potential treatment of rheumatoid arthritis, autoimmune skin diseases, and inflammatory bowel disease.
Figure 4. Engineering strategies for plant-derived exosome-like nanoparticles, including drug loading and surface modification to improve targeted delivery. Source: Zhao et al., International Journal of Molecular Sciences (2026) . Licensed under CC BY 4.0 .

Researchers are also developing ways to load PELNs with drugs or RNA molecules and modify their surfaces to improve delivery to specific cells or inflamed tissues. These approaches could eventually support more targeted treatments that regulate disease-associated inflammation while limiting unwanted effects elsewhere in the body.

However, most evidence remains preclinical, and important questions remain about nanoparticle composition, consistent manufacturing, long-term safety, and how reliably their biological contents influence human cells. Clinical trials will be needed to establish whether these approaches are safe and effective for people living with autoimmune disease.

The review highlights an emerging area of nanomedicine that could contribute to more precise approaches to autoimmune disease treatment.

Reference

Zhao, L., Hu, B., Ren, Z., Li, K., Ma, Y., Wang, L., & Liu, Y. (2026). Plant-Derived Exosome-like Nanoparticles: Biocompatible Vectors for Efficient Intervention of Autoimmune Diseases. International journal of molecular sciences, 27(21), 9866. https://doi.org/10.3390/ijms27219866